Your browser is no longer supported. Please, upgrade your browser.
IONS Ionis Pharmaceuticals, Inc. weekly Stock Chart
IONS [NASD]
Ionis Pharmaceuticals, Inc.
Index- P/E22.72 EPS (ttm)2.87 Insider Own0.30% Shs Outstand141.94M Perf Week8.33%
Market Cap9.24B Forward P/E269.13 EPS next Y0.24 Insider Trans-40.24% Shs Float127.76M Perf Month-3.48%
Income399.10M PEG0.46 EPS next Q-0.30 Inst Own92.60% Short Float10.07% Perf Quarter0.62%
Sales798.50M P/S11.58 EPS this Y139.20% Inst Trans9.97% Short Ratio12.01 Perf Half Y-18.10%
Book/sh9.05 P/B7.20 EPS next Y284.60% ROA15.00% Target Price69.53 Perf Year44.44%
Cash/sh15.94 P/C4.09 EPS next 5Y49.00% ROE37.70% 52W Range43.27 - 86.58 Perf YTD20.48%
Dividend- P/FCF58.44 EPS past 5Y41.70% ROI13.60% 52W High-24.78% Beta1.95
Dividend %- Quick Ratio9.90 Sales past 5Y32.40% Gross Margin57.50% 52W Low50.52% ATR2.22
Employees737 Current Ratio10.00 Sales Q/Q39.20% Oper. Margin11.90% RSI (14)47.92 Volatility3.91% 3.22%
OptionableNo Debt/Eq0.52 EPS Q/Q98.00% Profit Margin50.00% Rel Volume0.80 Prev Close66.20
ShortableYes LT Debt/Eq0.51 EarningsAug 07 BMO Payout0.00% Avg Volume1.07M Price65.13
Recom2.80 SMA20-0.78% SMA50-1.15% SMA200-0.68% Volume852,994 Change-1.62%
Sep-10-19Upgrade Bernstein Mkt Perform → Outperform
Aug-08-18Reiterated Stifel Hold $48 → $47
Aug-07-18Reiterated Stifel Hold $55 → $48
May-08-18Downgrade Evercore ISI Outperform → In-line
Oct-06-17Resumed Goldman Sell $30
Aug-17-17Initiated Evercore ISI Outperform $65
Aug-09-17Reiterated Stifel Hold $42 → $50
Mar-10-17Downgrade Goldman Neutral → Sell
Dec-28-16Reiterated BMO Capital Markets Outperform $61 → $68
Dec-27-16Reiterated Leerink Partners Mkt Perform $40 → $47
Dec-27-16Reiterated Laidlaw Buy $59 → $65
Nov-10-16Resumed Leerink Partners Mkt Perform
Aug-10-16Reiterated Piper Jaffray Overweight $36 → $46
Aug-03-16Initiated Morgan Stanley Equal-Weight $37
Aug-02-16Reiterated Needham Buy $55 → $64
Aug-02-16Reiterated Barclays Equal Weight $26 → $41
May-27-16Reiterated Needham Buy $88 → $55
Sep-16-19 07:00AM  Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting GlobeNewswire
Sep-05-19 09:17AM  If You Had Bought Ionis Pharmaceuticals (NASDAQ:IONS) Shares Three Years Ago You'd Have Made 107% Simply Wall St.
Sep-03-19 08:01AM  How Biotech Companies Are Targeting RNA to Cure Diseases Barrons.com
Aug-29-19 07:00AM  Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings GlobeNewswire
Aug-28-19 02:15PM  Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo Zacks
07:05AM  Ionis Pharmaceuticals to present at upcoming investor conferences PR Newswire
Aug-27-19 07:05AM  Ionis licenses hepatitis B program to GSK PR Newswire
Aug-22-19 08:15PM  Ionis Pharmaceuticals Inc (IONS) Chairman and CEO Stanley T Crooke Sold $1.6 million of Shares GuruFocus.com -5.96%
Aug-15-19 03:50PM  Ionis Pharmaceuticals, Inc. (IONS) Q2 2019 Earnings Call Transcript Motley Fool
Aug-14-19 01:47PM  Ionis Pharmaceuticals Looks to Partners to Pay the Bills Motley Fool
09:15AM  Market Takes Off After Tariffs Pushed Back Zacks
09:13AM  Edited Transcript of IONS earnings conference call or presentation 7-Aug-19 3:30pm GMT Thomson Reuters StreetEvents
08:53AM  3 Charts That Suggest Now Is the Time to Buy Into Biotech Investopedia
Aug-07-19 05:10PM  New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome GlobeNewswire +5.63%
08:15AM  Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:34AM  The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout Benzinga
07:00AM  Ionis Reports Second Quarter 2019 Financial Results PR Newswire
Aug-06-19 04:05PM  Akcea Reports Financial Results and Highlights for Second Quarter 2019 GlobeNewswire
04:05PM  Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy GlobeNewswire
08:54AM  Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet? Simply Wall St.
Jul-31-19 10:36AM  Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for Zacks
09:15AM  Rate Cut Wait Almost Over Zacks
Jul-30-19 10:38AM  Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for Zacks
07:05AM  Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast PR Newswire
Jul-22-19 08:15PM  Ionis Pharmaceuticals Inc (IONS) Chairman & CEO Stanley T Crooke Sold $702,500 of Shares GuruFocus.com
Jul-19-19 06:00AM  Ionis Pharmaceuticals IONS- 2019 Top Picks' Mid-Year Update MoneyShow
Jul-10-19 09:15AM  Late Surge Helps S&P Join NASDAQ in the Green Zacks
Jul-01-19 07:30AM  Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients PR Newswire
07:30AM  Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients GlobeNewswire
Jun-30-19 12:15PM  3 Top Biotech Stocks to Add to Your Watchlist Motley Fool
Jun-29-19 04:00AM  Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy GlobeNewswire
Jun-21-19 12:13PM  Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) A High Quality Stock To Own? Simply Wall St.
Jun-20-19 04:38PM  Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting GlobeNewswire
Jun-18-19 07:05AM  Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference PR Newswire
Jun-12-19 04:05PM  Ionis announces appointment of Joan E. Herman to its board of directors PR Newswire
Jun-11-19 07:26AM  Are Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Paying Above The Intrinsic Value? Simply Wall St.
Jun-06-19 07:05AM  Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders PR Newswire
Jun-03-19 12:18PM  Here's Why Mirati Therapeutics Is Jumping Today Motley Fool
May-28-19 07:00AM  Akcea Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-27-19 11:10AM  Novartis Gene Therapy Crosses The $2 Million Mark Will Others Follow? Investor's Business Daily
May-25-19 10:19AM  What Is Nektar Therapeutics' New Game Plan? Motley Fool
May-24-19 07:46PM  Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio Motley Fool
May-20-19 09:35PM  Edited Transcript of IONS earnings conference call or presentation 9-May-19 3:30pm GMT Thomson Reuters StreetEvents
12:04PM  Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock InvestorPlace
09:49AM  7 A-Rated Healthcare Stocks for Industry Expansion InvestorPlace
May-14-19 07:02PM  Biogens SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy GlobeNewswire
03:51PM  Ionis Pharmaceuticals Is 40% of the Way There Motley Fool
May-09-19 09:23PM  Ionis Pharmaceuticals, Inc. (IONS) Q1 2019 Earnings Call Transcript Motley Fool
04:11PM  Highly-Rated Biotech Post 106% Sales Growth In Profitable First Quarter Investor's Business Daily
08:45AM  Ionis Pharmaceuticals (IONS) Beats Q1 Earnings and Revenue Estimates Zacks
07:36AM  Ionis Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM  Ionis reports first quarter 2019 financial results PR Newswire
May-08-19 04:05PM  Akcea Reports Financial Results and Highlights for First Quarter 2019 GlobeNewswire
10:38AM  Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More Zacks
May-07-19 04:05PM  New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN) GlobeNewswire -7.04%
08:41AM  Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union GlobeNewswire
May-06-19 04:14PM  How Dow Jones' Pfizer Could Take On New Drugs From 2 Biotech Stocks Investor's Business Daily
07:05AM  Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients PR Newswire
May-02-19 10:33AM  Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
07:05AM  Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19) GlobeNewswire
May-01-19 09:15AM  S&P Ends a Strong April with 3rd Straight Record Close Zacks
07:05AM  Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases PR Newswire
Apr-28-19 11:19AM  Biogen says it will not give up on Alzheimers after failed trials MarketWatch
Apr-26-19 10:30AM  Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Q1 Release Zacks
Apr-25-19 03:47PM  Biogen Looks to 23 Clinical Programs for Growth Motley Fool
07:05AM  Ionis Pharmaceuticals to hold first quarter 2019 financial results webcast PR Newswire
Apr-24-19 09:15AM  Solid Earnings Boost S&P, NASDAQ to New Closing Highs Zacks
07:00AM  Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast GlobeNewswire
Apr-23-19 08:58AM  Is Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Apr-22-19 10:57AM  The Zacks Analyst Blog Highlights: Alteryx, CommScope, Ionis Pharmaceuticals and Apache Zacks
Apr-18-19 08:09PM  Hedge Funds Dropped The Ball On Ionis Pharmaceuticals, Inc. (IONS)? Insider Monkey
10:45AM  4 Large-Cap Stocks Worth Looking Into Right Now Zacks
Apr-17-19 04:52PM  Why A Highly Rated Biotech With A 54% Gain This Year Is Being Gutted Investor's Business Daily -12.74%
02:34PM  Here's Why Ionis Pharmaceuticals Slumped Today Motley Fool
01:54PM  Why A Highly Rated Biotech With A 54% Gain This Year Is Being Gutted Investor's Business Daily
09:15AM  NASDAQ Back Above 8,000 Zacks
Apr-11-19 08:00AM  5 Stocks to Sell as They Climb to New Highs InvestorPlace
Apr-10-19 09:15AM  S&P Streak Ends as Stocks Step Back Zacks
Apr-08-19 04:05PM  Ionis Pharmaceuticals to Provide Corporate Update at 2019 Annual Meeting of Stockholders PR Newswire
09:15AM  3 Stocks That Have Doubled and Still Have Room to Grow Motley Fool
Apr-04-19 02:49PM  1 Biotech That Biogen Should Buy ... but Probably Won't Motley Fool
10:23AM  Achillion Meets Enrollment Target in Kidney Disease Studies Zacks
Mar-28-19 04:41PM  Achillion Completes Enrollment in Rare Blood Disorder Study Zacks
Mar-27-19 09:15AM  S&P Fights Past Growth Concerns to Reclaim 2800 Zacks
Mar-25-19 07:05AM  Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors PR Newswire
Mar-15-19 04:05PM  Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19) GlobeNewswire
Mar-08-19 04:39PM  IBD Stock Of The Day Obliterates Earnings Views And Eyes New Buy Point Investor's Business Daily
12:27PM  6 of the Most Expensive Stocks That Could Go On Sale InvestorPlace
Mar-07-19 07:05AM  Ionis Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
Mar-05-19 12:22AM  Edited Transcript of IONS earnings conference call or presentation 27-Feb-19 4:30pm GMT Thomson Reuters StreetEvents
Mar-04-19 03:46PM  Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs Motley Fool
12:00AM  Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-01-19 03:48PM  Ionis Pharmaceuticals Inc (IONS) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
08:44AM  EU committee approves Akcea-Ionis drug for rare genetic disease Reuters
07:45AM  Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen) GlobeNewswire
Feb-27-19 07:52PM  Ionis Pharmaceuticals (IONS) Q4 2018 Earnings Conference Call Transcript Motley Fool +15.12%
02:35PM  Here's Why Ionis Pharmaceuticals Jumped Higher Today Motley Fool
07:00AM  Ionis Exceeds 2018 Financial Guidance PR Newswire
Feb-25-19 10:40AM  Novartis aims to pump up cardio business with Ionis deal Reuters
10:27AM  Novartis In-Licenses Rights to Heart Candidate From Ionis Zacks
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CROOKE STANLEY TChairman and CEOAug 21Option Exercise39.8710,000398,70079,634Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 21Sale72.1510,000721,50069,634Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 20Option Exercise39.872,00079,7407,532Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 20Option Exercise39.8710,000398,70079,634Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 20Sale71.002,000142,0005,532Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 20Sale71.0010,000710,00069,634Aug 22 06:41 PM
CROOKE STANLEY TChairman & CEOJul 18Option Exercise39.8710,000398,70079,634Jul 22 05:34 PM
CROOKE STANLEY TChairman & CEOJul 18Sale70.2510,000702,50669,634Jul 22 05:34 PM
McDevitt DamienChief Business OfficerJul 15Option Exercise0.003,54203,798Jul 17 05:39 PM
KLEIN JOSEPH IIIDirectorJul 03Option Exercise0.00667015,495Jul 03 06:46 PM
MUTO FREDERICK TDirectorJul 03Option Exercise0.00667012,683Jul 03 06:43 PM
LOSCALZO JOSEPHDirectorJul 03Option Exercise0.00667013,308Jul 03 06:39 PM
WENDER JOSEPH HDirectorJul 03Option Exercise0.00667061,805Jul 03 06:34 PM
WENDER JOSEPH HDirectorJul 02Option Exercise0.00889061,138Jul 03 06:34 PM
LOSCALZO JOSEPHDirectorJul 02Option Exercise0.00889012,641Jul 03 06:39 PM
MUTO FREDERICK TDirectorJul 02Option Exercise0.00889012,016Jul 03 06:43 PM
KLEIN JOSEPH IIIDirectorJul 02Option Exercise0.00889014,828Jul 03 06:46 PM
PARSHALL B LYNNEDirectorJul 02Option Exercise0.00889053,566Jul 03 06:49 PM
Monia Brett PChief Operating OfficerJul 02Sale66.4021013,94422,234Jul 02 08:50 PM
KLEIN JOSEPH IIIDirectorJul 01Option Exercise0.001,333013,939Jul 03 06:46 PM
MUTO FREDERICK TDirectorJul 01Option Exercise0.001,333011,127Jul 03 06:43 PM
LOSCALZO JOSEPHDirectorJul 01Option Exercise0.001,333011,752Jul 03 06:39 PM
WENDER JOSEPH HDirectorJul 01Option Exercise0.001,333060,249Jul 03 06:34 PM
BERTHELSEN SPENCER RDirectorJun 24Option Exercise16.3215,000244,800103,784Jun 26 06:52 PM
BERTHELSEN SPENCER RDirectorJun 24Sale63.6715,000955,11394,094Jun 26 06:52 PM
MUTO FREDERICK TDirectorJun 04Option Exercise16.3215,000244,80024,794Jun 06 06:35 PM
MUTO FREDERICK TDirectorJun 04Sale65.2915,000979,3509,794Jun 06 06:35 PM
MUTO FREDERICK TDirectorMay 06Option Exercise24.428,000195,36017,794May 08 06:16 PM
MUTO FREDERICK TDirectorMay 06Sale72.758,000582,0029,794May 08 06:16 PM
PARSHALL B LYNNEDirectorApr 29Option Exercise39.8750,0001,993,500102,677May 01 05:48 PM
PARSHALL B LYNNEDirectorApr 29Sale75.0150,0003,750,63552,677May 01 05:48 PM
CROOKE STANLEY TChairman and CEOApr 16Option Exercise31.161,00031,1556,232Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 16Option Exercise31.4620,000629,19882,954Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 16Sale84.751,00084,7505,532Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 16Sale84.6220,0001,692,50069,634Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 15Option Exercise10.821,00010,8206,532Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 15Option Exercise14.6910,000146,90079,634Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 15Sale85.251,00085,2505,532Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 15Sale85.2510,000852,50069,634Apr 17 07:30 PM
Geary Richard SSVP, DevelopmentApr 08Option Exercise42.5346,2401,966,46645,442Apr 10 06:24 PM
Geary Richard SSVP, DevelopmentApr 08Sale84.0146,2403,884,75321,442Apr 10 06:24 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 05Option Exercise61.682,252138,90318,925Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 05Sale84.752,252190,85716,673Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 04Option Exercise56.7636,6222,078,80935,165Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 04Sale83.7939,6223,319,92916,673Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 03Option Exercise61.687,654472,09927,327Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 03Sale84.837,654649,28919,673Apr 05 07:29 PM
WENDER JOSEPH HDirectorMar 19Sale79.6310,000796,25858,916Mar 20 06:05 PM
O'NEIL PATRICK R.SVP Legal & General CounselMar 18Option Exercise61.5728,8001,773,21648,473Mar 20 06:15 PM
O'NEIL PATRICK R.SVP Legal & General CounselMar 18Sale78.7928,8002,269,18719,673Mar 20 06:15 PM
PARSHALL B LYNNEDirectorMar 12Option Exercise39.878,334332,27761,011Mar 14 06:24 PM
PARSHALL B LYNNEDirectorMar 12Sale75.008,334625,05052,677Mar 14 06:24 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 27Option Exercise45.1126,8001,208,95233,773Mar 01 05:40 PM
PARSHALL B LYNNEDirectorFeb 27Option Exercise39.878,333332,23761,010Mar 01 05:56 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 27Sale68.0126,8001,822,58019,673Mar 01 05:40 PM
PARSHALL B LYNNEDirectorFeb 27Sale70.008,333583,31052,677Mar 01 05:56 PM
CROOKE STANLEY TChairman and CEOFeb 26Option Exercise39.8737,0001,475,190106,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 26Sale61.5437,0002,276,79969,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 25Option Exercise39.8740,0001,594,800109,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 25Sale60.0740,0002,402,70069,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 13Option Exercise33.126,904228,66610,832Feb 14 05:57 PM
CROOKE STANLEY TChairman and CEOFeb 13Option Exercise39.8740,0001,594,800109,634Feb 14 05:57 PM
CROOKE STANLEY TChairman and CEOFeb 13Sale60.006,904414,2405,532Feb 14 05:57 PM
CROOKE STANLEY TChairman and CEOFeb 13Sale60.1040,0002,404,02869,634Feb 14 05:57 PM
Geary Richard SSVP, DevelopmentFeb 13Sale60.0099959,94021,442Feb 14 05:51 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 12Option Exercise39.8727510,96419,948Feb 14 06:01 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 12Sale59.5027516,36319,673Feb 14 06:01 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 05Option Exercise39.8715,600621,97235,273Feb 05 06:05 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 05Sale59.5015,600928,20019,673Feb 05 06:05 PM
BENNETT C FRANKSVP, Antisense ResearchFeb 01Option Exercise14.699,013132,40133,541Feb 05 05:59 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 01Option Exercise39.874,000159,48023,673Feb 05 06:05 PM
BENNETT C FRANKSVP, Antisense ResearchFeb 01Sale58.299,013525,36824,528Feb 05 05:59 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 01Sale58.294,000233,16019,673Feb 05 06:05 PM
BENNETT C FRANKSVP, Antisense ResearchJan 15Option Exercise0.007,822027,218Jan 17 07:39 PM
Geary Richard SSVP, DevelopmentJan 15Option Exercise0.008,085024,942Jan 17 07:36 PM
HOUGEN ELIZABETH LSVP Finance & CFOJan 15Option Exercise0.007,891022,665Jan 17 07:35 PM
Monia Brett PChief Operating OfficerJan 15Option Exercise0.0010,006025,847Jan 17 07:34 PM
CROOKE STANLEY TChairman and CEOJan 15Option Exercise0.002,34606,474Jan 17 07:27 PM
CROOKE STANLEY TChairman and CEOJan 15Option Exercise0.0030,587082,320Jan 17 07:27 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 15Option Exercise0.007,823022,341Jan 17 07:24 PM
PARSHALL B LYNNEDirectorJan 15Option Exercise0.0020,656058,836Jan 17 07:19 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 03Option Exercise37.234,400163,80818,584Jan 03 07:50 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 03Sale54.804,400241,12014,584Jan 03 07:50 PM
Monia Brett PChief Operating OfficerJan 02Sale53.5021411,44915,837Jan 03 07:42 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 19Option Exercise7.252,06314,95716,837Dec 20 05:55 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 19Sale52.052,063107,37914,774Dec 20 05:55 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 18Option Exercise7.252,00014,50016,774Dec 20 05:55 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 18Sale52.002,000104,00014,774Dec 20 05:55 PM
Monia Brett PChief Operating OfficerNov 23Option Exercise14.6934,000499,46049,841Nov 26 08:01 PM
Monia Brett PChief Operating OfficerNov 23Sale55.0034,0001,870,05815,841Nov 26 08:01 PM
BENNETT C FRANKSVP, Antisense ResearchNov 01Option Exercise14.6912,500183,62531,896Nov 01 07:34 PM
BENNETT C FRANKSVP, Antisense ResearchNov 01Sale49.5412,500619,24519,396Nov 01 07:34 PM